A Multicenter, Randomized, Controlled, Double-blind Pivotal Phase 3 Trial to Evaluate the Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years

VLA1553-322 is a multicenter, prospective, randomized, double-blind, phase 3 clinical trial evaluating VLA1553 in comparison to a comparator (Nimenrix®) for each stratum (age group). At least 3,000 male and female healthy children aged 1 to 11 years will be enrolled and randomized 3:1 to either VLA1553 (n=2,250) or comparator (Nimenrix®) (n=750).

开始日期2026-02-06

申办/合作机构

VALNEVA Austria GmbH

NCT07163845

/ Enrolling by invitationN/A

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

This is a cross-sectional serosurvey using household cluster sampling conducted before the VLA1553 pilot vaccination strategy will be implemented in about 10 municipalities in Brazil.

开始日期2025-09-22

申办/合作机构

VALNEVA Austria GmbH

[+2]

NCT06928753

/ Recruiting临床4期IIT

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La R?union

Against the backdrop of a growing chikungunya epidemic in La R?union, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ? vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.

开始日期2025-04-18

申办/合作机构-

100 项与 Chikungunya virus vaccine (Valneva) 相关的临床结果

登录后查看更多信息

100 项与 Chikungunya virus vaccine (Valneva) 相关的转化医学

登录后查看更多信息

100 项与 Chikungunya virus vaccine (Valneva) 相关的专利（医药）

登录后查看更多信息

项与 Chikungunya virus vaccine (Valneva) 相关的文献（医药）

2025-12-31·Emerging Microbes & Infections

Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages

Article

作者: Mader, Robert ; Weaver, Scott C. ; Beasley, David W.C. ; Hochreiter, Romana ; Bitzer, Annegret ; Buerger, Vera ; Brasel, Trevor L. ; Smith, Jeanon ; Torres, Maricela ; Kosulin, Karin ; Dubischar, Katrin

Cross-neutralization is generally a prerequisite for cross-protection of vaccines against diseases caused by heterologous viruses. Using sera obtained from a randomized clinical phase 3 trial in adults, we investigated the cross-neutralization activity of VLA1553, a vaccine recently approved to prevent chikungunya disease. Analysed in a plaque reduction neutralization test, the three major chikungunya virus (CHIKV) lineages, namely the East Central South African, the West African, and the Asian lineage, were inhibited by CHIKV-specific neutralizing antibodies present in the sera from vaccinated humans. This effect was independent of the time elapsed since vaccination. Moreover, the magnitude of the immune response was similar to the antibody levels detected in sera from convalescent chikungunya patients. Thus, VLA1553 has the potential to diminish the burden of chikungunya disease on a global scale.Trial registration: ClinicalTrials.gov identifier: NCT04546724.

2025-11-06·Eurosurveillance

Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025

Article

作者: Simone, Benedetto ; Lienert, Florian

Older adults are at increased risk of severe chikungunya. Some countries advise against vaccinating ≥ 60 or ≥ 65-year-olds with the licenced live-attenuated vaccine (CHIKV LA, IXCHIQ), following severe adverse event (SAE) reports. A virus-like particle vaccine (CHIKV VLP, VIMKUNYA) is licensed in the United States (US), EU/EEA and the United Kingdom. Up to 31 August 2025, over 12,500 doses were administered in US and Germany; no SAEs in ≥ 65-year-olds were reported. Early post-authorisation data support its favourable safety profile in ≥ 65-year-olds.

2025-10-01·LANCET INFECTIOUS DISEASES

More data needed on the FDA's decision to suspend Ixchiq

作者: The Lancet Infectious Diseases

226

项与 Chikungunya virus vaccine (Valneva) 相关的新闻（医药）

2025-11-14

·近岸蛋白

起底全球200+新型疫苗管线：扎堆的临床及商业化布局，谁能成为“疫苗王者”？

新冠疫情后，疫苗开发迎来了前所未有的变革期。在2024-2025这一关键节点，全球疫苗产业在传统平台优化与新型平台迭代上同步加速。整体疫苗开发正朝着“通用化、可及化、智能化”方向迈进。在此行业快速扩充的关口，我们尝试对2024-2025期间，新型疫苗及传统疫苗的突破性进展进行了整体梳理，尤其是已经迈入临床转化或商业化阶段的高价值项目，力图以全球性的眼光，观察未来疫苗行业的腾飞新方向。一、新型疫苗平台快速迭代 2024-2025年间，新型疫苗技术迎来了加速应用与产业化突破。在2024-2025年间，国内RNA疫苗（mRNA/circRNA/saRNA）获批临床项目近20项，进入“多病种切入”“版本更新”阶段。重组亚单位疫苗及病毒样颗粒(VLP)平台也通过配方更新、佐剂与结构设计等，继续在监管与覆盖能力上取得实质性进展。 RNA疫苗（mRNA／circRNA/saRNA） 2024年5月1日—University of Florida（UF Health Cancer Center）团队发布其mRNA疫苗用于脑瘤（glioblastoma）治疗的初步人体研究成果[1]。该团队开发了一种基于mRNA的肿瘤疫苗（使用患者自身肿瘤细胞信息+复杂递送机制）并在成人患者中观察到“在48小时内使肿瘤从免疫冷态变为免疫热态”的免疫反应。对mRNA平台而言，它标志着mRNA疫苗不仅限于传染病防控，还可用于复杂肿瘤免疫治疗，体现平台通用性的突破。也说明mRNA的递送和免疫激活机制正被重大改进。对于circRNA而言，最大的突破性进展莫过于连续三个项目进入临床阶段，原研单位均来自中国。转录本生物放射性口干症的临床项目于2024年10月份获批，环码生物用于治疗缺血性心脏病环状RNA项目于2025年1月获批临床，圆因生物环状RNA药物TI-0093注射液于2025年8月获临床试验默示许可，该项目用于治疗HPV16阳性的晚期复发或转移性实体瘤。临床项目的增多意味着在逐渐突破工艺的同时，质量研究也开始逐步完善。相较于circRNA，saRNA进展更快，2023年11月，日本厚生劳动省批准了CSL与Arcturus therapeutics联合开发的自复制RNA(saRNA)新冠疫苗：ARCT-154（一款saRNA-LNP冻干制剂），是第一个获批上市的saRNA疫苗。2025年9月份，美国公司Replicate Bioscience公布了其狂犬病saRNA临床项目RBI-4000的8个月耐久性分析数据，在0.1–10 μg剂量方案下，在受试者中可在最长8个月仍检测到中和抗体，且用多种衰减模型比较显示其抗体半衰期与/或耐久性与传统灭活疫苗相当或更优[2]。证明了RNA平台向“更低剂量（成本）、更广覆盖”方向的可行性，是RNA平台从“短期应急”向“长期常规”转变的关键里程碑。表1、截至目前国内获批紧急使用或进入临床的mRNA疫苗（部分清单，novoprotein整理，如需完整清单，请在文末添加近岸蛋白小助手）亚单位／重组蛋白疫苗 2024年8月30日，Novavax（公司）获得美国FDA对其更新配方蛋白/佐剂COVID-19疫苗的紧急使用授权（EUA）[3]。是蛋白/佐剂平台在法规层面被再次认可为主流抗 SARS-CoV-2的可用选项，表明蛋白疫苗（非mRNA）仍具快速迭代并被监管接受的能力。 2024年9月4日，Vaxcyte公司宣布其31价肺炎球菌结合疫苗（VAX-31）在一项针对1015名50岁及以上健康成人的1/2期临床试验中取得了积极结果，并决定推进至更高3期临床[4]。代表多价蛋白/结合疫苗通过扩大覆盖血清型（价型扩展）直接提升公共卫生价值，代表结合疫苗在覆盖率的竞争力上取得实质进展。表2、截至目前进入商业化阶段的亚单位/重组蛋白疫苗（部分清单，novoprotein整理，如需完整清单，请在文末添加近岸蛋白小助手）病毒样颗粒疫苗（VLP） VLP在2024–2025年的真正突破是由临床成功转向监管批准与商业化上市，实现质的飞跃。 2025年3月18日，Bavarian Nordic（公司）推出并在美欧获批商业化其VLP-based Chikungunya疫苗VIMKUNYA™用于12岁以上人群，并启动2-11岁儿童的第III期试验[5]。这是首个以VLP技术在成人/青少年中获准并商业化的针对新兴病原体（Chikungunya）的疫苗，把VLP从“临床候选/研究”阶段推进到使用阶段，证明其在安全性与免疫原性上既能满足监管要求又具备商业化条件。 2024年2月19日，阿斯利康以11亿美元金额完成了对Icosavax公司的收购，并推进 IVX-A12（RSV+hMPV组合蛋白VLP疫苗）至临床中后期[6]。II期数据表明，IVX-A12在接种疫苗一个月后可引发针对RSV和hMPV强大免疫应答，该疫苗已进入到III期临床。大型制药公司对VLP平台的并购与推进说明VLP已被视为可产业化、可规模生产且商业价值明确的平台。对行业来说，意味着资本与产能将加速VLP的广泛应用。表3、截至目前进入商业化阶段的VLP疫苗（novoprotein整理，如有错漏，欢迎指正）二、传统疫苗平台的精进在2024-2025年间，传统疫苗平台（如减毒/灭活/病毒载体等）虽然相较于新型疫苗平台显得“稳重”，但同样在给药方式、靶点拓展、特殊人群应用、监管规范化等方面有所突破，显著强化了作为“疫苗产业基本盘”的角色。下面列出几个突破性进展：给药方式创新 2024年4月15日，牛津大学公布了通过气溶胶方式给予减毒版Tuberculosis疫苗（BCG疫苗）的一项人体挑战模型研究[7]，研究中将BCG通过喷雾方式进入肺部，研究其在近似自然感染途径下的安全性与耐受性。这一研究强调传统减毒疫苗不仅在经典的“肌肉/皮下注射”路径上可靠，而且通过更接近病原自然侵入途径（肺部喷雾）进行的给药方式研究，代表了传统平台在“给药方式”与免疫原性增强上的改进。靶点拓展 2024年9月10日，法国Valneva公司在《Journal of Travel Medicine》杂志上发表其基孔肯雅热减毒活疫苗VLA1553(IXCHIQ®)相关数据[8]，随后该款疫苗成为首款获得FDA批准的基孔肯雅热减毒病毒疫苗用于成人免疫。标志着减毒病毒疫苗平台在全球公共卫生病原体（蚊媒病毒）中的应用扩展，从传统的减毒疫苗（如麻疹、风疹）走向新的病毒类型，从而强化了减毒平台在“新病原／少有疫苗”领域中的价值。免疫受损人群应用 2025年6月11日，由康希诺生物与中国军事医学科学院生物工程研究所共同研究的腺病毒5型载体的新冠疫苗（Ad5nCoV）在HIV感染者（PLWH）人群中进行研究，显示安全且免疫反应持续至少一年[9]。表明腺病毒载体平台正在扩展至免疫受损人群的应用，这加强了其在“高风险群体疫苗策略”中的地位。监管规范化 2024年12月20日，中国国家药典委员会发布新版《多糖结合疫苗质量控制技术指南（征求意见稿）》，涉及多糖结合疫苗中“偶联工艺”“纯化工艺”“载体蛋白选择”等[10]。该指南的发布体现监管层面对多糖-蛋白结合疫苗平台的进一步规范与推动，意味着该平台进一步规范化。未来，无论是新型疫苗还是传统疫苗，技术趋势都将持续向多病种覆盖与多平台融合发展。人工智能的快速进步，为疫苗从抗原设计、结构优化到免疫效果预测提供了前所未有的研发效率。随着多技术平台的疫苗项目不断实现从早期研究到临床验证，再到商业化落地的突破，意味着在面对快速变异的病原体与潜在大流行时，人类将具备更敏捷的响应能力、更高的制造灵活性以及更可持续的免疫保障体系。这不仅代表疫苗研发范式的革新，也预示着疫苗产业正迈入一个以智能化、模块化的新阶段。近岸蛋白加速新型疫苗疗法的研究开发与转化应用近岸蛋白提供新型疫苗研发过程中的全流程解决方案，涵盖RNA疫苗、亚单位疫苗、VLP疫苗多核心技术平台，具备从抗原设计、候选分子筛选、工艺建立，到质量控制与评价的能力，团队成员拥有多年人用与兽用疫苗开发经验。 11月14-16日，2025中国疫苗行业协会学术年会在福建厦门召开，本次大会将有中国疫苗行业各研究院所、高等院校、药物研发与生产企业等行业专家展开深入交流，设置了多个分会场主题。近岸蛋白诚邀您在厦门国际会议展览中心，B12展位进行交流。主题报告 11月15日下午15：10，近岸蛋白董事长朱化星博士将在核酸疫苗分论坛进行题为《高通量RNA合成平台助力候选分子快速筛选》的主题报告，解读高通量应用平台助力新型疫苗开发的进展。展会信息提前看近岸蛋白在B12号展台期待与您相遇，共同探讨疫苗行业的前沿技术。扫描下方二维码添加小助手微信（备注：新型疫苗），将会邀您加入新型疫苗技术交流群，定期分享并探讨新型疫苗技术的最新发展。近岸蛋白小助手 RNA疫苗方面，近岸蛋白支持mRNA、circRNA、saRNA多种技术开发路线，覆盖从候选分子序列优化、通量筛选与生物学评估等过程服务，拥有GMP级T7 RNA聚合酶、加帽酶等关键原料，并完成全套产品FDA DMF备案，已助力20余家客户完成中美IND申报。在亚单位疫苗开发中，近岸蛋白拥有计算机辅助抗原结构设计与蛋白分析改造能力，支持通过大肠杆菌、酵母、真核、昆虫多表达系统匹配小规模到放大生产。VLP疫苗表达体系具备高效自组装能力，独立开发生产工艺具备高纯度高均一性特点。会议日程参考文献 [1] UF-developed mRNA vaccine triggers fierce immune response to fight malignant brain tumor. UF Health Cancer Institute [2] Christian J. Maine, Gaelle Picarda, Shigeki J. Miyake-Stoner et al. Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial. Nature. Published 2025 Sep 24. [3] FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants. U.S.FOOD&DRUG官网 [4] Summary of VAX-31 Adult 50+ Phase 1/2 Study Topline Data Findings. Vaxcyte官网 [5] Bavarian Nordic官网 [6] AstraZeneca官网 [7] Breakthrough aerosol human infection model gives hope for future tuberculosis vaccine development. University of Oxford News. [8] Lin H Chen, Andrea Fritzer, Romana Hochreiter et al. From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine. Journal of Travel Medicine. Published 2024 Sep 10. [9] Pedro Cahn, Luis Barreto, Maria Ines FigueroaImmune et al. response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH). Plos One. Published 2025 Jun 11. [10] 中国食品药品国际交流中心官网苏州近岸蛋白质科技股份有限公司（简称近岸蛋白）深耕重组蛋白行业十余年，是一家专注于蛋白质技术与应用解决方案的高新技术企业，主营业务为生物药、体外诊断、mRNA疫苗药物、生命科学基础研究等领域的原料与技术解决方案，包括靶点及因子类蛋白、重组抗体、酶及试剂的研发、生产和销售及相关技术服务。公司在上海、苏州和菏泽建有研发、生产基地。访问www.novoprotein.com.cn或致电400-600-0940。点击“阅读原文”，了解会议日程

信使RNA疫苗上市批准临床研究

2025-11-06

·FiercePharma

Without enough shareholder support, Bavarian Nordic's proposed private equity buyout fails

Sixty percent of Bavarian Nordic's shareholders agreed to a takeover by Nordic Capital and Permira, falling below the required threshold of 66.7% acceptance. A proposed buyout of Bavarian Nordic by a private equity consortium didn’t win over enough shareholder support, laying to rest months of back-and-forth.Nordic Capital and Permira—under the name of a newly formed company called Innosera—had upped their “best and final price” to 250 Danish Krone per share ($38.61) last month. Under the terms of the offer, the deal hinged on 66.7% of Bavarian Nordic’s shareholders agreeing to the takeover by Nov. 5.As only 60% of shareholders accepted the deal, the prospective buyers have effectively withdrawn their bid as the offer has “irrevocably lapsed,” Bavarian Nordic explained in a Nov. 6 press release. Shares of Bavarian fell by 20% as of early Thursday afternoon, sinking to $9.61 over the previous close of $12.02.When the company’s board unanimously backed the initial “attractive proposal” in July, following what it described as “intense negotiations,” it highlighted the “ample capital and resources” that the consortium offered to accelerate Bavarian’s growth strategy.However, seeds of shareholder disagreement were quickly sown when Denmark’s biggest pension fund, ATP, objected to the transaction as “neither the timing nor the price of the presented offer reflects the opportunities we see in the company,” VP of ATP’s Danish equities, Claus Berner Moller, told Fierce Pharma in a statement at the time. ATP is Bavarian Nordic’s largest shareholder with a stake above 10%.Nonetheless, the vaccine maker’s CEO, Paul Chaplin, was hopeful that the private equity firms could help turn Bavarian’s “unloved” portfolio of assets into growth drivers, he told Bloomberg in August.The sweetened offer in October was meant to reflect “greater clarity on several key macroeconomic risks” and allow shareholders to realize their investment at a further improved valuation “without bearing the risk, continued volatility and additional capital requirements” associated with Bavarian’s long-term growth journey, Permira’s managing healthcare director and head of DACH, Florian Kreuzer, explained in the offer notice.At the time, the consortium calculated that about 25.7% of Bavarian’s share capital was so far on board with the deal. The 66.7% threshold for the final offer was a lowered standard from the previous acceptance condition of 75%, which was also knocked down from the original requirement of 90% shareholder acceptance.Now, the drugmaker has resolved to continue as an independent company that is “well positioned to continue to grow,” chair of the board of directors, Luc Debryune, said in the release.“The Board of Directors has the full confidence in the management's continued execution of the strategy, including considerations for ways to accelerate value creation,” Debryune noted.However, the company’s board and management now “see an opportunity to rebuild a value-creating dialogue” with shareholders and stakeholders, Debryune added. An upcoming shareholders’ information meeting will see discussions on the state of the business, its strategy and financial ambitions and the “need to ensure continuity of leadership.” Bavarian Nordic’s most recent financial report (PDF) recorded a second-quarter sales increase of 16% and gains of 33% over the first half of the year compared to last year. With the results, the company raised the lower end of its 2025 revenue guidance to a new window of DKK 6 billion ($927 million) to DKK 6.6 billion ($1.02 billion).Chaplin called the sales performance a reflection of the company’s “successful commercial transformation” over the past few years and highlighted the launch of its chikungunya vaccine, Vimkunya. The vaccine won U.S. approval in February under a broader label than Valneva’s first-to-market rival Ixchiq and quickly secured a recommendation from the CDC’s vaccine advisory committee.Bavarian’s vaccine portfolio could benefit from a resurgence of global chikungunya disease outbreaks, especially as Ixchiq was wiped off the U.S. market in August when the FDA suspended its license based on “serious safety concerns.” However, vaccine makers across the industry face an uncertain future amid shifting U.S. vaccine policies under a Robert F. Kennedy-led Department of Health and Human Services.

疫苗上市批准财报

2025-10-31

·科普中国

基孔肯雅热：被蚊子“叮”出来的流行病

图文简介：鉴于目前特效药和疫苗的不足，预防基孔肯雅热的核心策略是防蚊。2025年夏季，中国南方部分地区报告了本地基孔肯雅热疫情。病例多与白纹伊蚊（俗称“花蚊子”）叮咬有关。患者出现突发高热、严重关节痛、皮疹等症状，有人甚至因为疼痛而无法正常行走。这是近年来我国首次出现较大规模的基孔肯雅热疫情，提示公众需要进一步了解这种由蚊子传播的传染病。 1952年，非洲坦桑尼亚暴发一场神秘疫情，患者突发高烧，并伴有严重的、无法动弹的关节痛。当地土著语言形容为“基孔肯雅热”，意为关节弯曲的疾病。在过去73年中，基孔肯雅热（CHIKF）多次暴发，已扩散到100多个国家，报道了超过400万例病例。基孔肯雅热是由基孔肯雅病毒（CHIKV）引起的，是一种蚊媒病毒性疾病，由伊蚊传播。基孔肯雅病毒属于披膜病毒科（Togaviridae），甲病毒属（Alphavirus)，是膜包被的单股正链RNA病毒。病毒通过其表面的E糖蛋白介导细胞入侵。埃及伊蚊原产于非洲，主要栖息在热带和亚热带地区。白纹伊蚊起源于亚洲，在热带和温带气候中定居。2005年，基孔肯雅病毒的囊膜E1糖蛋白发生了一个关键突变（A226V），使其对白纹伊蚊的感染性大幅增强，使得该病毒的传播地区进一步扩张。这两种伊蚊都表现出对人类宿主的强烈性偏好。感染基孔肯雅热表现为突然发热、关节炎、皮疹、肌痛等，通常在感染后2-6日出现。随着对虫媒病毒的关注度不断提高，病例和监测报告中也出现了一些不太常见的非典型基孔肯雅热感染表现，如格林-巴利综合征、脑炎、癫痫、意识模糊和中风等神经系统症状，在部分病例中观察到心、肝、肾等器官损伤。部分研究报道，约30–40% 的患者进展为慢性基孔肯雅关节炎（特征为持续性或变形性关节炎），影响人们正常生活工作，是21世纪初严重影响人类公共卫生安全的虫媒传染病之一。基孔肯雅病毒究竟是如何入侵细胞的呢？只有弄清楚了这个基本科学问题，有效开发出疫苗和新药。2018年，有研究团队表明MXRA8是基孔肯雅病毒的功能性受体。中国科学院微生物研究所高福院士团队通过X射线衍射晶体“看到了”病毒结合受体的细节，解析了CHIKV表面囊膜E蛋白和受体MXRA8复合物的结构，揭示其3：3的分子相互作用模式，即三个E蛋白与三个受体形成稳定复合物，并指出MXRA8的茎区是病毒入侵必需的，相关成果2019年发表在Cell杂志。MXRA8，也叫DICAM、ASP3和limitrin，高表达于成纤维细胞、关节滑膜细胞，与基孔肯雅热关节剧痛的临床症状相关。靶向CHIKV E囊膜蛋白和MXRA8的结合面设计小分子药物、筛选特异性单克隆抗体已经成为一个重要的研究方向。早诊断很重要，如何确定患者感染了基孔肯雅病毒呢？由于基孔肯雅热的临床症状与其它蚊媒疾病相似，仅根据临床表现诊断较为困难。目前RT-PCR依然是早期诊断的金标准，血清学（IgM/IgG）在后期有辅助价值。迄今为止，尚无获得许可的基孔肯雅病毒药物，凸显药物研发的紧迫性。接种疫苗是预防基孔肯雅热感染的有效策略。目前疫苗（VLA1553）于2023年11月获得美国食品药品监督管理局（FDA）许可。VLA1553是一种减毒活疫苗，该毒株nsp3基因中的多个氨基酸被删除。临床试验表明，该疫苗的血清保护率高达95%以上。但由于收到了4份新的严重不良事件报告，美国FDA已于2025年8月25日决定暂停其在美国的许可证。Bavarian Nordic公司研发的病毒样颗粒疫苗Vimkunya®在2025年初先后获得了美国FDA和欧洲药品管理局（EMA）的批准，可用于12岁及以上人群的接种。说明人类已经在预防基孔肯雅热上迈出关键一步，但疫苗的长期安全性和普及性仍需进一步观察。因此，研发出安全、有效的预防性疫苗依然迫在眉睫。鉴于目前特效药和疫苗的不足，预防基孔肯雅热的核心策略是防蚊。建议居民居家安装纱窗，清除积水容器，使用电蚊拍、杀虫剂等除蚊；外出穿浅色长袖衣物，并携带含避蚊胺的驱蚊液；避开疫区雨季旅行。通过切断病毒传播媒介，有效防控疫情。本文为科普中国·创作培育计划扶持作品出品丨科普中国科普部监制丨中国科学技术出版社有限公司、北京中科星河文化传媒有限公司作者丨金夕月博士审核丨宋豪中科院北京生物院研究员来源: 科普中国创作培育计划内容资源由项目单位提供

疫苗临床研究

100 项与 Chikungunya virus vaccine (Valneva) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
基孔肯雅热	美国	VALNEVA Austria GmbH	2023-11-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04650399 (VLA1553-321, GlobeNewswire) 人工标引	临床3期	基孔肯雅热	754	IXCHIQ® Chikungunya Vaccine	顧築鏇餘簾顧淵積選襯(鑰簾鏇窪遞遞齋簾艱鑰) = 艱築顧獵淵獵網簾艱鹽窪蓋膚壓廠廠鏇艱蓋衊 (窪構膚夢願顧鬱繭範襯 ) 更多	积极	2025-01-20
NCT04838444 (VLA1553-303, GlobeNewswire) 人工标引	临床3期	基孔肯雅热	278	IXCHIQ®	顧顧壓觸淵糧鏇艱製襯(觸鹽選醖鏇憲鑰鏇艱憲) = 範齋範範築積鹹鹹簾鹽憲鏇積窪壓襯廠顧構艱 (範遞鬱顧衊觸齋製願願 )	积极	2024-12-03
NCT04650399 (VLA1553, Pubmed \| Lancet Infect Dis)	临床3期	基孔肯雅热	754	live-attenuated chikungunya virus vaccine (VLA1553)	網積鹽簾鬱鹽餘選遞顧(餘鑰獵簾築繭廠顧壓醖) = Most (365 [93%] of 393) adverse events were of mild or moderate intensity, VLA1553 was generally well tolerated. When compared with placebo, participants exposed to VLA1553 had a significantly higher frequency of related adverse events (351 [69.9%] of 502 vs 121 [48.0%] of 252; p<0.0001), mostly headache, myalgia, fatigue, and fever. Among four reported serious adverse events (three in the VLA1553 group and one in the placebo group), one was classified as possibly related to VLA1553: a high-grade fever. Among 20 adverse events of special interest (ie, symptoms suggesting chikungunya-like disease), 16 were classified as related to trial vaccination (15 in the VLA1553 group and one in the placebo group), with severe symptoms reported in four participants (fever, headache, or arthralgia). 17 adverse events of special interest resolved within 1 week. Among 85 participants with arthralgia (68 in the VLA1553 group and 17 in the placebo group), eight adolescents had short-lived (range 1-5 days), mostly mild recurring episodes (seven in the VLA1553 group and one in the placebo group). The median duration of arthralgia was 1 day (range 1-5 days). The frequency of injection site adverse events for VLA1553 was higher than in the placebo group (161 [32%] vs 62 [25%]), but rarely severe (two [<1%] in the VLA1553 group and one [<1%] in the placebo group). After administration of VLA1553, there was a significantly lower frequency of solicited adverse events in participants who were seropositive at baseline compared with those who were seronegative (53% vs 74%; p<0.0001) including headache, fatigue, fever, and arthralgia. 顧範膚網願襯獵蓋積鏇 (廠願願膚衊淵壓願餘憲 ) 更多	积极	2024-09-01
				live-attenuated chikungunya virus vaccine (Placebo)
NCT04650399 (VLA1553-321, Company_Website) 人工标引	临床3期	基孔肯雅热	234	VLA1553	構簾糧憲觸觸製構願醖(遞齋築願築鬱襯構築鏇) = 願夢範淵鹽選構齋築鑰鹽築窪淵膚淵糧積鹹鑰 (膚鏇齋蓋繭淵淵範醖憲 )	积极	2024-05-13
NCT04546724 (GlobeNewswire) 人工标引	临床3期	基孔肯雅热	316	IXCHIQ	醖膚蓋鑰製衊範衊齋鹹(壓選繭築範壓廠鏇壓夢) = 觸壓淵範簾淵獵廠觸餘齋積簾鹹鹹願夢鏇鹹衊 (繭襯衊築齋遞鑰鏇齋鬱 ) 更多	积极	2023-12-04
NCT04650399 (VLA153-321, GlobeNewswire) 人工标引	临床3期	基孔肯雅热	250	VLA1553	襯蓋廠憲鹹繭襯觸築觸(鬱廠廠獵鑰網範獵鑰遞) = VLA1553 administered as a single-dose was generally well tolerated in adolescents aged 12 to <18 years, irrespective of previous CHIKV infection and showed a similar safety profile as reported in adults 餘夢憲鹽願顧艱鹽選積 (獵齋鹽遞齋夢選觸鹹願 ) 更多	积极	2023-11-23
NCT04546724 (FDA) 人工标引	临床3期	基孔肯雅热	4,115	IXCHIQ	醖鑰範選鹽觸範選憲觸(壓網鏇積願糧築淵艱簾) = 襯憲夢選網襯範醖淵獵鑰築範選鬱憲製繭襯網 (齋積顧觸窪夢廠願繭衊, 96.7 ~ 99.8) 更多	积极	2023-11-09
				Placebo	醖鑰範選鹽觸範選憲觸(壓網鏇積願糧築淵艱簾) = 淵餘鹹繭網餘積艱齋餘鑰築範選鬱憲製繭襯網 (齋積顧觸窪夢廠願繭衊, 0.0 ~ 3.8) 更多
NCT04786444 (CTgov)	临床3期	基孔肯雅热	409	Biological Vaccine VLA1553 (VLA1553 Lot 1)	製鹽艱夢廠醖壓構簾網(範鏇鑰鑰襯鹽願繭鹹膚) = 襯範鑰構構積觸構窪範壓襯鏇襯遞鏇窪襯蓋襯 (鹹蓋繭獵獵願鏇積簾獵, 夢衊鬱觸獵鬱獵範製艱 ~ 壓餘遞衊觸鑰顧遞夢鑰) 更多	-	2023-09-28
				Biological Vaccine VLA1553 (VLA1553 Lot 2)	製鹽艱夢廠醖壓構簾網(範鏇鑰鑰襯鹽願繭鹹膚) = 廠廠願鬱衊構鏇醖廠鑰壓襯鏇襯遞鏇窪襯蓋襯 (鹹蓋繭獵獵願鏇積簾獵, 憲鑰選壓鏇憲壓蓋鑰餘 ~ 糧範鑰淵糧範築觸壓糧) 更多
NCT04801420 (VLA15-221, CTgov)	临床2期	莱姆病	625	VLA15 (Group 1: VLA15)	遞衊鹹獵簾餘積壓鹹鏇 = 淵願窪廠蓋齋顧顧選醖鏇醖網鑰積艱繭網製積 (艱繭繭蓋製繭鏇齋構齋, 鹽齋鑰襯簾膚夢築壓鹽 ~ 選糧廠夢鹹鑰繭壓範範) 更多	-	2023-06-07
				Placebo+VLA15 (Group 2: VLA15 + Placebo)	遞衊鹹獵簾餘積壓鹹鏇 = 蓋糧夢網憲醖鹽積觸襯鏇醖網鑰積艱繭網製積 (艱繭繭蓋製繭鏇齋構齋, 築夢鹽夢膚鏇夢選鬱窪 ~ 遞壓顧憲積淵窪鬱糧網) 更多
NCT04546724 (Corporate Publications) 人工标引	临床3期	基孔肯雅热	4,115	VLA 1553	顧築膚襯憲窪壓網壓鑰(鏇壓觸醖獵蓋顧構餘觸) = 製窪膚積鹹醖簾膚簾膚鑰觸鬱鬱夢襯膚簾鑰鏇 (齋淵簾鹽顧襯鏇願網窪, 96.7 ~ 99.8) 更多	积极	2022-10-13
				Placebo	顧築膚襯憲窪壓網壓鑰(鏇壓觸醖獵蓋顧構餘觸) = 衊製鏇餘餘夢蓋簾遞繭鑰觸鬱鬱夢襯膚簾鑰鏇 (齋淵簾鹽顧襯鏇願網窪, 0.0 ~ 3.8) 更多